Breaking News

Pulmatrix to Merge with Cullgen

Will form a new Nasdaq-listed company focused on developing targeted protein degraders for cancer and other diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Pulmatrix Inc., a clinical-stage biopharmaceutical company, has announced a merger agreement with Cullgen Inc., a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE platform to discover and advance therapeutics for the treatment of cancer and other diseases.   Cullgen utilizes its proprietary technology platform, uSMITE, featuring novel E3 ligands, to build next-gen targeted protein degraders and degrader-antibody conjugates (D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters